search

Active clinical trials for "Ovarian Neoplasms"

Results 181-190 of 2005

Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage...

Stage IIIC Fallopian Tube CancerStage IIIC Ovarian Cancer4 more

This phase II trial studies how well hyperthermic intraperitoneal chemotherapy works in improving quality of life in patients with stage IIIC-IV ovarian, fallopian tube, or primary peritoneal cancer. In hyperthermic intraperitoneal chemotherapy, the chemotherapy is warmed before being used and may help the drugs get into the cancer cells better, minimize the toxicity of the drugs on normal cells, and help to kill any cancer cells left over after surgery.

Recruiting20 enrollment criteria

Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and...

BRCA1 Gene MutationBRCA2 Gene Mutation18 more

This phase II trial studies how well pembrolizumab works in treating participants with cancer that has spread to other places in the body, has come back or has spread to nearby tissues or lymph nodes. Monoclonal antibodies such as, pembrolizumab, may interfere with the ability of tumor cells to grow and spread.

Recruiting39 enrollment criteria

A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With...

Ovarian Neoplasms

This study will evaluate the efficacy and safety of niraparib and novel treatment combinations of niraparib as described within each cohort-specific supplement in participants with ovarian, fallopian tube, or primary peritoneal cancer. Cohort A (single arm) includes participants with recurrent ovarian cancer. Cohort B will not be initiated. Cohort C (randomized-2 arms) includes participants with newly diagnosed ovarian cancer.

Recruiting67 enrollment criteria

An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial...

Ovarian NeoplasmsPeritoneal Neoplasms1 more

This multicenter prospective study will evaluate the safety and efficacy of Avastin (bevacizumab) in routine clinical practice in patients with advanced/metastatic epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer. Data will be collected from eligible patients until death, withdrawal of consent, loss to follow-up, or study closure.

Recruiting2 enrollment criteria

Intraperitoneal Infusion of ex Vivo-cultured Allogeneic NK Cells in Recurrent Ovarian Carcinoma...

Recurrent Ovarian CarcinomaRecurrent Fallopian Tube Carcinoma1 more

This study investigates an innovative treatment for recurrent ovarian cancer exploiting ex vivo-generated allogeneic natural killer (NK) cells with or without preceding non-myeloablative conditioning chemotherapy.

Recruiting18 enrollment criteria

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced...

Solid TumorColorectal Cancer10 more

The main purpose of this study is to establish the safety and the recommended dose of TRK-950 in combination with FOLFIRI, Gemcitabine / Cisplatin, Gemcitabine / Carboplatin, Ramucirumab / Paclitaxel, PD1 inhibitors (Nivolumab or Pembrolizumab), and Imiquimod Cream, Bevacizumab, Gemcitabine / Carboplatin / Bevacizumab, Topotecan, and Pegylated liposomal doxorubicin (PLD) for selected advanced solid tumors.

Recruiting32 enrollment criteria

NeoVax With Nivolumab in Patients With Ovarian Cancer

Ovarian Cancer

This research study is evaluating a new type of vaccine called "Personalized NeoAntigen Cancer Vaccine" in combination with Nivolumab (Opdivo®) for ovarian cancer.

Recruiting38 enrollment criteria

ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer

Malignant Ovarian Epithelial TumorPlatinum-Resistant Fallopian Tube Carcinoma8 more

This phase II trial studies the side effects of ONC201 and paclitaxel and how well they work in treating patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer that has come back (recurrent), or that does not respond to treatment (refractory). ONC201 is the first in its class of drugs that antagonize some specific cell receptors on cancer cells, leading to their destruction. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ONC201 and paclitaxel may work better in treating patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer compared to paclitaxel alone.

Recruiting25 enrollment criteria

Niraparib Plus Anlotinib for Recurrent Ovarian Cancer

Ovarian CarcinomaSurvival Outcomes7 more

This is a phase II trial to explore efficacy and safety of niraparib in combination with anlotinib based on CA 125 level in newly diagnosed ovarian cancer. After completion of 1st-line platinum-based chemotherapy with a normal CA-125 concentration, in patients with CA-125 increased > 35U/ml, and with no evidence of imaging recurrence, niraparib and anlotinib are used as 1st maintenance therapy for newly diagnosed advanced ovarian cancer after achieving complete or partial remission to platinum-containing chemotherapy. The primary objective of this study is to explore the efficacy of niraparib combined with anlotinib based on CA 125 level in newly diagnosed ovarian cancer with no evidence of imaging recurrence. A total o f36 patients will be enrolled in this study.

Recruiting48 enrollment criteria

Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer

Ovarian NeoplasmsCarcinoma9 more

This is a study of pembrolizumab (MK-3475, KEYTRUDA®) in combination with lenvatinib (E7080) for the treatment of platinum sensitive recurrent ovarian cancer. Participants will receive pembrolizumab and lenvatinib.

Recruiting50 enrollment criteria
1...181920...201

Need Help? Contact our team!


We'll reach out to this number within 24 hrs